Medical and Health Industry Weekly Report | "Yangqi Yixincore" Secures Tens of Millions of Yuan in Pre-A Round Financing; The Anxiety of Young People is Facilitating a "Big Business" for Blood Glucose Meters.
In recent years, the healthcare industry has witnessed a continuous emergence of innovations and has developed into one of the most active sectors. 36Kr has witnessed and accompanied the growth of innovative enterprises in this field and brought professional voices to the industry.
For this reason, 36Kr has launched the "Healthcare Industry Weekly Report" column, which will be released regularly to provide readers with industry information from multiple perspectives such as capital, policies, finance, and new products.
Please check the Healthcare Industry Weekly Report for November 24. This weekly report includes financing news in the healthcare field this week.
Financing and Investment
- Precision radiotherapy enterprise "Yangqi Yixin" obtains tens of millions of yuan in Pre-A round financing
Recently, the precision nuclear medical enterprise "Yangqi Yixin" has completed a Pre-A round financing of tens of millions of yuan. This round of financing is led by Anfeng Ventures, and the raised funds will be mainly used for the marketing of approved products, the R&D and approval of new products, and the expansion of the pet radiotherapy market. Yangqi Yixin was established in 2021 and focuses on the development of nuclear medical and tumor radiotherapy products. The company's founding team is composed of experts in the fields of nuclear medicine, nuclear physics, and artificial intelligence from Stanford, Alibaba, and other domestic and foreign institutions. For a long time, radiotherapy treatment has problems such as extensive intraoperative treatment plans, insufficient process accuracy, and overly long treatment courses. To this end, Yangqi Yixin empowers precision radiotherapy through its independently developed optical navigation technology. The company's existing product portfolio includes the optical body surface monitoring product "Qishi", the low-dose CT enhancement product "Qingying", and the SRT low-energy superficial radiotherapy equipment, etc.
- BaiFu Laser completes tens of millions of yuan in B+ round financing
Suzhou BaiFu Laser Technology Co., Ltd. announced the completion of tens of millions of yuan in B+ round financing. This round of financing is exclusively invested by Mifang Health Fund. This round of financing is mainly used for the company's capacity expansion, the continuous exploration of the global market, the improvement of the brand image, and the innovation and iteration of self-developed products. BaiFu Laser is committed to the R&D, production, and sales of medium and high-end medical aesthetic photoelectric equipment. The company has more than 10 core products and more than 100 intellectual property certificates, and it is also a national high-tech enterprise. At present, the company's products have been exported to more than 70 countries and regions, and the company's business has achieved a growth of more than 100% compared to the performance in 2023.
- Tiangang Yinuo completes tens of millions of yuan in pre-A+ round financing
Hefei Tiangang Immune Pharmaceutical Co., Ltd. announced the completion of tens of millions of yuan in pre-A+ round financing. This round of financing is led by Hefei Chanyetou Capital, and several investment institutions such as Zhongke Chuangxing, USTC Valley, and Haiyuan Capital jointly participate. This round of financing will provide important financial support for Tiangang Yinuo's product R&D to promote the clinical trial of core products and the development of new products, and accelerate the clinical transformation of innovative immune drugs. Tiangang Yinuo is a biotech company founded by the R&D team led by Professor Tian Zhigang, a double academician of the Chinese Academy of Engineering and the European Academy of Sciences, dedicated to the development of innovative target immune drugs. The R&D team has focused on anti-tumor immunity research for more than 30 years. In the past 10 years, the team has used the anti-cancer principle of the human body's natural immunity to discover new targets for anti-cancer immune drugs and the R&D of antibody-based immune drugs.
- Shenova Technology completes tens of millions of yuan in financing
Shenova Technology (Shanghai) Co., Ltd. has completed the Pre-A round financing, with a total financing amount of tens of millions of yuan. It is reported that this round of financing is led by Cedar Creek Capital, and the raised funds will be used for the company's clinical trial research application of small-caliber artificial blood vessels and to accelerate the clinical transformation of the company's world-leading bio-micro-nano material technology. Shenova Technology was founded in 2015 by Professor Li Song, an expert in biomedical materials and former director of the Department of Bioengineering at the University of California, Los Angeles (UCLA), in collaboration with Dr. Dai Weimin, the president of the Berkeley Shanghai Alumni Association, with the support of the Zhangjiang Berkeley Innovation Center. It focuses on the development and application of bio-micro-nano technology in the fields of high-value medical devices and new materials. The company has established a leading bio-micro-nano technology application and clinical transformation platform and developed a series of products based on bio-micro-nano materials.
- BaiMingXinKang completes a new round of financing of hundreds of millions of yuan
BaiMingXinKang, a biopharmaceutical company dedicated to providing breakthrough immunotherapy solutions, announced the completion of a new round of financing of hundreds of millions of yuan. This round of financing is jointly invested by PICC Capital Equity, Qingsong Capital, a well-known industrial investment institution, and other well-known institutions and industrial investors. Founded in 2018, BaiMingXinKang is committed to the research and development of a new generation of specific immunotherapies for allergic diseases and autoimmune diseases. The company has a wholly-owned subsidiary in Europe with integrated production, research, and sales, and has dozens of commercialized products. The company is actively expanding the global market and promoting the clinical development and commercialization of innovative allergy and immune therapy products that have been listed in Europe in China.
Healthcare 36Kr
- Young people's anxiety is facilitating a "big business" in blood glucose meters | Healthcare 36Kr
First of all, this is not for treating diseases, An Yu wants to emphasize this point.
Her sugar control experiment began with a small health salon. The presenter said, "Don't take health for granted," and then explained in detail the impact of blood sugar imbalance on the body, such as fatigue, sugar addiction, weight gain, and hormonal disorders. An Yu has a paranoid pursuit of "efficiency" and "optimization". If her work state is affected by the drowsiness caused by the rise in blood sugar after a meal, or if she has the urge to overeat due to excessive stress, "she really can't stand it".
Therefore, purchasing a blood glucose meter to monitor the impact of the food she consumes on her blood sugar has become the simplest way to maintain her mental state. After being "dominated" by the numbers on the APP for several weeks, An Yu successfully quit coffee and ice cream, fell in love with drinking plain water, and felt that "it is easier for her to concentrate during the day".
On Xiaohongshu, posts sharing experiences of controlling sugar and losing weight with a dynamic blood glucose meter are the real "traffic password". Among the hundreds of comments at every turn, netizens enthusiastically share which one is the "blood sugar assassin" between carrots and oat milk, how to consume fruits with less sugar intake, and how many units the blood sugar has risen after eating a certain food... (Click here for details)
Editor: Hu Xiangyun